GRI Bio GRI 深滬

已收盤 05-08 16:00:00 美东时间

2.245

-0.005

-0.22%

華盛通

立即下載

最高2.32
今開2.30
成交量 1.77万股
最低 2.23
昨收 2.25
總市值 324.41万
52周最高 80.36
市盈率 ^靜 --
換手率 1.23%
52周最低 2.10
委比 73.86%
總股本 144.50万
歷史最高 64792072.80
量比 0.45
振幅 4.00%
歷史最低 2.23
每手 1
風險率 21.68%

個股概要

財務分析

公司資料

分紅派息

分時圖
日k
周k
月k

相關新聞

White House Grid Move Could Boost Electrification Stocks And ETFs, Says Anthony Pompliano

The White House's designation of grid infrastructure as essential to national defense is expected to accelerate investment into electrification.

04-27 17:38
GRI Bio Receives Notice Of Allowance From UAE Patent Office For UAE Patent Titled Prevention And Treatment Of Inflammatory Conditions

Issued claims further strengthen global intellectual property portfolio supporting immune cell modulation platform and expand strategic presence in a high-growth international marketLA JOLLA, CA, April 08, 2026 (GLOBE

04-08 20:32
美股大行评级 | 甲骨文绩后分歧大！小摩上调评级至"超配"，目标价缺降至210美元；科尔士百货、AVAV、Blend Labs、Domo遭多家大行下调评级

今日重点评级关注：LUCID CAPITAL MARKETS：上调INmune Bio评级至"买入" 目标价从2美元升至9美元；Clear Street：维持MoonLake Immunotherapeutics Class A"买入"评级，目标价从45美元升至70美元

03-12 12:34
Ascendiant Capital Maintains Buy on GRI Bio, Lowers Price Target to $40

Ascendiant Capital analyst Edward Woo maintains GRI Bio (NASDAQ:GRI) with a Buy and lowers the price target from $1008 to $40.

03-11 20:44
After Trump's SOTU, Hyperscalers Told to Build Their Own Power — Grid ETFs In Focus

AI's electricity boom meets Trump's SOTU policy shift. Utilities and smart grid ETFs may be the real winners — or losers.

02-26 05:04
GRI Bio Reports Positive Phase 2a Results in Idiopathic Pulmonary Fibrosis

GRI Bio Reports Positive Phase 2a Results in Idiopathic Pulmonary Fibrosis GRI Bio Inc. announced additional positive Phase 2a clinical data for its pipeline targeting Idiopathic Pulmonary Fibrosis (IPF). The results, which include biomarker data indicating improvements in fibrosis and lung repair,

02-17 22:15
GRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” Segment

GRI Bio, a biotechnology company developing NKT cell modulators for inflammatory, fibrotic, and autoimmune diseases, participated in a Virtual Investor "What This Means" segment. Marc Hertz, CEO, discussed the company's recently reported positive Phase 2a data for GRI-0621 in Idiopathic Pulmonary Fibrosis (IPF), highlighting biomarker improvements in fibrosis drivers and lung repair. GRI Bio's therapies target iNKT cells to interrupt disease prog...

02-17 14:15
EXCLUSIVE: 'Inference Infrastructure Gap To Widen' — Bitcoin Miner Cango's AI Pivot Signals An ETF Opportunity

Crypto miner Cango is pivoting to AI infrastructure. A senior Cango executive cites growing power demand as a reason. This shift hides ETF opportunities.

02-14 22:02
GRI Bio shares are trading higher. The company reported FY25 financial results.

GRI Bio shares are trading higher. The company reported FY25 financial results.

02-04 21:58
GRI Bio FY25 Net Loss $12M

GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of immune cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases today

02-04 21:56

派息除權日	每股總股息	派息日期
2023-03-23	0.63	2023-03-28
2022-12-22	0.53	2022-12-29
2022-09-22	0.45	2022-09-29
2022-06-23	0.48	2022-06-30
2022-03-24	0.52	2022-03-31
2021-12-22	0.56	2021-12-29
2021-09-23	0.44	2021-09-30
2021-06-17	0.47	2021-06-24
2021-03-18	0.51	2021-03-25
2020-12-22	0.64	2020-12-30
2020-09-17	0.35	2020-09-24
2020-06-18	0.42	2020-06-25
2020-03-19	0.68	2020-03-26
2019-12-19	0.51	2019-12-27
2019-09-19	0.27	2019-09-26
2019-06-20	0.37	2019-06-27
2019-03-21	0.35	2019-03-28
2018-12-20	0.41	2018-12-27
2018-09-20	0.22	2018-09-27
2018-06-21	0.44	2018-06-28
2018-03-22	0.22	2018-03-29
2017-12-21	0.95	2017-12-28
2017-09-21	0.33	2017-09-27
2017-06-21	0.35	2017-06-28
2016-12-21	0.46	2016-12-29
2016-09-21	0.38	2016-09-28
2016-06-22	0.31	2016-06-29
2016-03-23	0.37	2016-03-31
2015-12-23	0.21	2015-12-31
2015-09-23	0.13	2015-09-30
2015-06-24	0.68	2015-07-01
2015-03-25	0.44	2015-04-01
2014-12-24	0.41	2015-01-02
2014-09-24	0.24	2014-10-01
2014-06-25	0.39	2014-07-02
2014-03-26	0.22	2014-04-02
2013-12-26	0.17	2014-01-03
2013-09-25	0.23	2013-10-02
2012-12-26	2.23	2013-01-03
2012-09-26	0.23	2012-10-03
2012-06-20	0.26	2012-06-27
2012-03-21	0.15	2012-03-28
2011-12-21	0.18	2011-12-28
2011-09-21	0.20	2011-09-28
2011-06-22	0.28	2011-06-29
2011-03-23	0.61	2011-03-30
2010-12-21	1.12	2010-12-29
2010-09-22	0.18	2010-09-29
2010-06-23	0.21	2010-06-30
2010-03-24	0.43	2010-03-31
2009-12-29	1.03	2010-01-06
2009-09-29	0.08	2009-10-06
2009-06-29	0.57	2009-07-07
2008-12-29	0.49	2009-01-05

公司名稱	GRI Bio
行業分類	--
業務描述	GRI Bio, Inc. engages in the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. It focuses on its lead program, GRI-0621, an inhibitor of type 1 invariant Natural Killer T (iNKT) cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The company was founded in May 2009 and is headquartered in La Jolla, CA.

GRI Bio GRI 深 滬

2.245

個股概要

財務分析

公司資料

相關新聞

分紅派息

相關新聞

公司簡介

GRI Bio GRI 深滬